PVM 및 FBRM 기반 인라인 모니터링을 통한 indomethacin-saccharin 공결정의 생성 메커니즘이해 = Understanding the Mechanism of Indomethacin-Saccharin Co-crystal Formation Using In-line Monitoring System based on PVM and FBRM

국문 초록 (Abstract)

난용성 약물의 용해도를 증가시키고 안정성을 향상하기 위한 제약 공결정은, 미국 FDA가 지난 2016년 8월에 공결정을 solvate의 특별한 경우라고 정의를 수정하면서, 개량신약의 개발에 더욱 박차를 가할 것으로 추측된다. 본 연구에서는 모델 조합으로 잘 알려진 indomethacin-saccharin 공결정을 반용매 방법으로 제조할 때, 인라인 모니터링 기법을 적용하여, 반용매의 주입속도에 따른 indomethacin 준 안정상의 일시적인 생성 및 indomethacin-saccharin 공결정의 생성을 관찰하고 메커니즘을 제안하고자 하였다. 그간 인라인 모니터링을 위해서 매우 다양한 분석도구가 연구되어 왔는데, 본 연구에서는 PVM (particle vision measurement)와 FBRM (focused beam reflectance measurement)를 조합하여 공결정화 공정에서의 변화를 실시간으로 측정하였다. 공결정화 결과물의 오프라인 분석은 PXRD (powder x-ray diffraction)와 DSC (Differential scanning calorimeter)를 이용하여 수행하였다. 반용매의 주입 속도에 따라서 공결정이 생성되는 경로에 분명한 차이가 있음을 관찰하였으며, 이러한 상관 관계의 이해를 통해서 제약학적 특성이 더욱 일정하고 품질이 보증된 indomethacin-saccharin Co-crystal을 얻는 조건을 확립하였다. 본 연구결과, PVM과 FBRM을 조합한 인라인 모니터링은 제약 공결정 제조공정에서 활용성이 매우 높은 기술이라고 할 수 있다.

다국어 초록 (Multilingual Abstract)

Pharmaceutical co-crystals primarily to improve the solubility as well as stability of insoluble drug are to be investigated more intensively for IMDs as US FDA has reclassified co-crystal as a special case of solvates in August this year. In this study, we proposed a mechanism of indomethacin-saccharin co-crystal formation and the creation of transient indomethacin meta-stable form using in-line monitoring tools with the addition rate of anti-solvent as a critical process parameter. Among various instruments, we combined PVM (particle vision measurement) and FBRM (focused beam reflectance measurement) for the in-line monitoring of anti-solvent co-crystallization process. The off-line characterization of resulting powders was carried out employing the PXRD (powder x-ray diffraction) and DSC (differential scanning calorimeter). It was observed that the pathway to the final IMC-SAC co-crystal was significantly dependent upon the anti-solvent addition rate. The process conditions to obtain high quality co-crystal powder effectively were established. Consequently, we concluded that in-line monitoring combing the PVM and FBRM should be useful for the in-line monitoring of pharmaceutical co-crystallization processes.

참고문헌 (Reference)

1 김정연, "의약품의 국제적 품질 경쟁력 확보를 위한 의약품실사상호협력기구(PIC/S)와한국의 GMP 비교연구" 대한약학회 57 (57): 432-441, 2013

2 "http://www.yonhapnews.co.kr/bulletin/2016/07/27/0200000000AKR 20160727096700017.HTML?input=1195m"

3 "http://www.dailypharm.com/News/184408"

4 "http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id=713"

5 Stegemann, S., "When Poor Solubility Becomes an Issue: From early Stage to Proof of Concept" 31 (31): 249-261, 2007

6 Alonzo, D., "Understanding the Behavior of Amorphous Pharmaceutical Systems During Dissolution" 27 (27): 608-618, 2010

7 Borka, L., "The Polymorphism of Indomethacin, New Modifications, Their Melting Behaviour and Solubility" 11 : 295-303, 1974

8 Qi, S., "The Development of Modulated, Quasi-Isothermal and Ultraslow Thermal Methods as a Means of Characterizing the α to γ Indomethacin Polymorphic Transformation" 9 : 1087-1099, 2012

9 Csermely, P., "Structure and Dynamics of Molecular Networks: A novel Paradigm of Drug Discovery: A comprehensive Review" 138 (138): 333-408, 2013

10 Bipul Sarma, "Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals" 한국화학공학회 28 (28): 315-322, 2011

11 Bhugra, C., "Role of Thermodynamic, Molecular and Kinetic Factors in Crystallization From the Amorphous State" 97 (97): 1329-1349, 2008

12 Chen, X., "Reactivity Differences of Indomethacin Solid Forms with Ammonia Gas" 124 : 15012-15019, 2002

13 De Beer, T. R., "Raman Spectroscopy as a Process Analytical Technology Tool for the Understanding and the Quantitative in-line Monitoring of the Homogenization Process of a Pharmaceutical Suspension" 131 (131): 1137-1144, 2006

14 Neervannan, S., "Preclinical Formulations for Discovery and Toxicology:Physicochemical Challenges" 2 (2): 715-731, 2006

15 Jia, C.-Y., "Polymorphic Transformation of Pravastatin Sodium Monitored Using Combined Online FBRM and PVM" 12 (12): 2008

16 Wang, X., "Phase Characterization of Indomethacin in Binary Solid Dispersions with PVP VA64 or Myrj 52" 345 : 95-100, 2007

17 Takiyama, H., "Operation Design for Controlling Polymorphism in the Anti-solvent Crystallization by Using Ternary Phase Diagram" 88 : 1242-1247, 2010

18 Turner, J. R., "New Drug Development" Springer 21-34, 2010

19 Liu, X., "Monitoring of Antisolvent Crystallization of Sodium Scutellarein by Combined Fbrm-pvm-nir" 100 (100): 2011

20 Liu, X., "Monitoring of Antisolvent Crystallization of Sodium Scutellarein by Combined FBRM-PVM-NIR" 100 (100): 3-, 2011

21 Kelly, A. L., "Monitoring Ibuprofen-Nicotinamide Cocrystal Formation During Solvent Free Continuous Cocrystallization (SFCC) Using Near Infrared Spectroscopy as a PAT Tool" 426 (426): 15-20, 2012

22 Khomane, K. S., "Molecular Understanding of the Compaction Behavior of Indomethacin Polymorphs" 10 : 631-639, 2013

23 Hancock, B. C., "Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition Temperatures" 12 (12): 799-806, 1995

24 Chang, J. W., "Metastable Zone Prediction Model for Industrial Crystallization" 10 (10): 25-30, 2007

25 Genck, W., "Make The Most of Antisolvent Crystallization"

26 Lin, S. Y., "Isolation and Solid-state Characteristics of a New Crystal Form of Indomethacin" 81 (81): 572-576, 1992

27 Wu, T., "Inhibiting Surface Crystallization of Amorphous Indomethacin by Nano Coating" 23 (23): 5148-5153, 2007

28 Surwase, S. A., "Indomethacin: New Polymorphs of an Old Drug" 10 : 4472-4480, 2013

29 Alsaidan, S. M., "Improved Dissolution Rate of Indomethacin by Adsorbents" 24 : 389-394, 1998

30 U. S. Department of Health and Human Services Food and Drug Administration, "Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance"

31 Su, M., "FBRM and PVM Investigations of the Double Feed Semi-Batch Crystallization of 6-Aminopenicillanic Acid" 3 (3): 282-288, 2009

32 Majid Saeedi, "Enhancement of Dissolution Rate of Indomethacin: Using Liquisolid Compacts" 10 (10): 25-34, 2011

33 Laitinen, R., "Emerging Trends in the Stabilization of Amorphous Drugs" 453 : 65-79, 2013

34 Andronis, V., "Effects of Sorbed Water on the Crystallization of Indomethacin From the Amorphous State" 86 (86): 346-351, 1997

35 Carpentier, L., "Dynamics of the Amorphous and Crystalline α-, γ-Phases of Indomethacin" 110 : 457-464, 2005

36 Li, P., "Developing Early Formulations: Practice and Perspective" 341 (341): 1-19, 2007

37 Greco, K., "Crystallization of Amorphous Indomethacin During Dissolution: Effect of Processing and Annealing" 7 (7): 1406-1418, 2010

38 Andronis, V., "Crystal Nucleation and Growth of Indomethacin Polymorphs From the Amorphous State" 271 (271): 236-248, 2000

39 이민정, "Controlling the polymorphism of carbamazepine-saccharin cocrystals formed during antisolvent cocrystallization using kinetic parameters" 한국화학공학회 32 (32): 1910-1917, 2015

40 Chun, N. -H., "Characteristics of Indomethacin-Saccharin (IMC-SAC) Co-Crystals Prepared by an Anti-Solvent Crystallization Process" 85 (85): 854-861, 2013

41 Hancock, B. C., "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems" 86 (86): 1-12, 1997

42 Leyssens, T., "Carine Baudry and Maria Luisa Escudero Hernandez, Optimization of a Crystallization by Online FBRM Analysis of Needle-Shaped Crystals" 413-426, 2011

43 Di, L., "Bridging Solubility Between Drug Discovery and Development"

44 Savolainen, M., "Better Understanding of Dissolution Behaviour of Amorphous Drugs by in Situ Solid-state Analysis Using Raman Spectroscopy" 71 (71): 71-79, 2009

45 Wang, I.-C., "Anti-Solvent Co-Crystallization of Carbamazepine and Saccharin" 450 (450): 311-322, 2013

46 Engers, D., "A solid-state Approach to Enable Early Development Compounds: Selection and Animal Bioavailability Studies of an Itraconazole Amorphous Solid Dispersion" 99 (99): 3901-3922, 2010

47 Baird, J. A., "A classification System to Assess the Crystallization Tendency of Organic Molecules From Undercooled Melts" 99 (99): 3787-3806, 2010